Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Extracellular vesicle delivery of myristoylated Cas9 highlights chromatin accessibility as an efficacy barrier in prostate cancer

Molecular Therapy(2025)10.1016/j.ymthe.2025.11.037Source: DataRank Database

Extracellular vesicle delivery of myristoylated Cas9 highlights chromatin accessibility as an efficacy barrier in prostate cancer is a research paper published in Molecular Therapy (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenIDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Shuoshuo Wang ORCID

Live enrichment

PubMed:41365293

NIH

Grant: P01AI179405

NIH

Grant: U54HL165440

National Cancer Institute

Grant: P30CA06516

National Cancer Institute

Grant: 5P30CA06516

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12925767/

publisherhttps://api.elsevier.com/content/article/PII:S1525001625010238?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001625010238?httpAccept=text/plain